| 商品名称 | Daptomycin Hospira |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Soft Tissue Infections;Skin Diseases, Bacterial |
|---|
| 通用名/非专利名称 | daptomycin |
|---|
| 活性成分 | daptomycin |
|---|
| 产品号 | EMEA/H/C/004310 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | J01XX09 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | Yes |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2017/03/22 |
|---|
| 上市许可开发者/申请人/持有人 | Pfizer Europe MA EEIG |
|---|
| 人用药物治疗学分组 | Antibacterials for systemic use |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2017/01/26 |
|---|
| 欧盟委员会决定日期 | 2025/09/11 |
|---|
| 修订号 | 15 |
|---|
| 治疗适应症 | Daptomycin is indicated for the treatment of the following infections. Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice. Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI. Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2018/04/13 |
|---|
| 最后更新日期 | 2025/09/17 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/daptomycin-hospira-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/daptomycin-hospira |
|---|